HSV在肿瘤治疗中的优势.pdf

SCIENCE CHINA Life Sciences ? The Author(s) 2013. This article is published with open access at S /scp *Corresponding author (email: zhaoyp8028@) ? REVIEW ? April 2013 Vol.56 No.4: 298–305 doi: 10.1007/s11427-013-4466-4 Advance in herpes simplex viruses for cancer therapy LIU ShangLong, DAI MeiHua, YOU Lei ZHAO YuPei* Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing 100730, China Received November 12, 2012; accepted February 27, 2013 Oncolytic virotherapy is an attractive approach that uses live viruses to selectively kill cancer cells. Oncolytic viruses can be genetically engineered to induce cell lyses through virus replication and cytotoxic protein expression. Herpes simplex virus (HSV) has become one of the most widely clinically used oncolytic agent. Various types of HSV have been studied in basic or clinical research. Combining oncolytic virotherapy with chemotherapy or radiotherapy generally produces synergic action with unclear molecular mechanisms. Arming HSV with therapeutic transgenes is a promising strategy and can be used to comple- ment conventional therapies. As an efficient gene delivery system, HSV has been successfully used to deliver various immuno- modulatory molecules. Arming HSV with therapeutic genes merits further investigation for potential clinical application. oncolytic viruses, herpesvirus, virotherapy, cancer, gene therapy Citation: Liu S L, Dai M H, You L, et al. Advance in herpes simplex viruses for cancer therapy. Sci China Life Sci, 2013, 56: 298–305, doi: 10.1007/s11427- 013-4466-4 Cancer cells are still difficult to destroy at present. Five- year survival rates for pancreatic, liver and lung cancer re- main disappointing. It is reported that 15 million new cancer cases and 10 million new deaths are expected in 2020 [1]. Carcinogenesis is a multi-step process involving var